, therefore, has 9,480 rooms under its management across 14 countries. For the Company’s performance in 2019, the Company reported the net profit including attributable to non-controlling interest of THB 605
or up by 4.11% and net profit of 1,248.47 million Baht, an increase of 202.25 million Baht or up by 19.33%. This was the result of our ability to control and manage expenses effectively, together with
follows For the three months in Q1/2018 ended March 31, 2018 The company had the operating result for the three months ended March 31, 2018 show a net loss of Baht 6.28 million, compare to the same period
ขายและบริการ – ต้นทุนขายและบริการ (ไม่รวมรายได้อื่น) Q3 2561 Q3 2560 YoY change YoY % change หน่วย: ลา้นบาท รายได้จากการขายและบรกิาร 301.56 201.46 100.10 50% ก าไรจากอัตราแลกเปลีย่น 0.00 0.00 0.00 0
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
Position 31 Dec 18 31 Dec 17 Change Cash and cash equivalent 4,023 8,396 - 4,373 Inventories 14,452 9,662 4,790 Current Assets 20,779 19,762 1,017 Net PPE 17,370 3,854 13,516 Intangible Assets-Net 494 482 30
Fair in Chiang Mai, Khon Kaen and Songkhla (Hat Yai), generating satisfactory same-store sales in the second quarter of 2019. This resulted in the company having total income and net profit of 17,565.41
performance in the second quarter shows total revenue of 16,464.72 million Baht, whilst net profit stood at 1,312.56 million Baht; this represents growth of 4.38% and 16.03% respectively compared to the same
2019. This resulted in the company having total income and net profit in the first nine- month period of Baht 50,493.89 million and Baht 4,428.72 million respectively, increasing 3.35% and 12.78% from
2016 Pe rfo rm an ce Group Revenues 3,292 2,897 Group Sales Volume (k tons) 182 187 Group EBITDA 213 109 Group Net Profit (Loss) 65 (30) HR C HRC Sales (k tons) 182 187 HRC Production Volume (k tons) 190